<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel>
  <title>The Peptide Record — Updates</title>
  <link>https://thepeptiderecord.org/updates/</link>
  <description>What changed on The Peptide Record: new Library pages, Register corrections, legal-status changes, and FDA warning-letter findings.</description>
  <language>en-us</language>
  <item>
    <title>12 new Library pages: fertility hormones, lipoglycopeptide antibiotics, EPO/CSF drugs</title>
    <link>https://thepeptiderecord.org/library/</link>
    <guid isPermaLink="false">2026-09-12-12 new Library pages: fertility hormones, lipoglycopeptide antibiotics, EPO/CSF drugs</guid>
    <pubDate>Sat, 12 Sep 2026 12:00:00 GMT</pubDate>
    <description>Follitropin Alfa/Beta, Menotropins, Lutropin Alfa, Choriogonadotropin Alfa, and Thyrotropin Alfa join the fertility/diagnostic-hormone cluster; Telavancin, Dalbavancin, and Oritavancin cover the lipoglycopeptide antibiotics; Epoetin Alfa, Darbepoetin Alfa, Filgrastim, and Pegfilgrastim cover the erythropoietin and colony-stimulating-factor drugs. The Library now stands at 111 ingredient pages.</description>
  </item>
  <item>
    <title>Correction: two duplicate Register assessments merged</title>
    <link>https://thepeptiderecord.org/register/</link>
    <guid isPermaLink="false">2026-09-12-Correction: two duplicate Register assessments merged</guid>
    <pubDate>Sat, 12 Sep 2026 12:00:00 GMT</pubDate>
    <description>Ancient Nutrition and Garden of Life's collagen-peptide products had each been independently assessed twice in separate research rounds without a duplicate check. Both duplicates have been merged into a single, more detailed entry, and the public &quot;products assessed&quot; count corrected down from 139 to 137.</description>
  </item>
  <item>
    <title>Two standing automations now watch this site for us</title>
    <link>https://thepeptiderecord.org/about/</link>
    <guid isPermaLink="false">2026-09-12-Two standing automations now watch this site for us</guid>
    <pubDate>Sat, 12 Sep 2026 12:00:00 GMT</pubDate>
    <description>A weekly pass re-checks Register categories for new or reassessment-due brands, and a separate weekly pass re-checks existing FDA warning-letter findings for status changes (closeout letters, new letters) — both land Sunday evening for Monday-morning review, and nothing publishes without a human check first.</description>
  </item>
</channel></rss>
